WW surge after GLP-1 compounding announcement not justified after study, Barclays says
by
Contributor since / Followers
Contributor since / Followers
3 months ago
patty_c/iStock Unreleased via Getty Images
“We do not view GLP-1 compounding as a sustainable long-term business model, and note that scale compounding is viable only while these branded weight loss drugs remain on the shortage list,” Davis said.
More on WW International
- WW International: The Party Won’t Last Long
- WW International: There May Never Be A Resurrection
- WW International, Inc. (WW) Q2 2024 Earnings Call Transcript
- WW International surges as Morgan Stanley says GLP-1 entry ‘not too late’
- WeightWatchers cashes in on popularity of weight loss drugs with compounded semaglutide